Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bridging the gap: ctDNA, genomics, and equity in breast cancer care

16 Aug 2025

Abstract excerpt

Circulating tumor DNA (ctDNA) has emerged as a powerful tool in precision oncology, offering a noninvasive approach to tumor profiling, minimal residual disease (MRD), and treatment monitoring. In breast cancer, ctDNA has shown promise in both metastatic and early-stage settings. However, its application and benefits have not been equitably realized across all populations. In this review, we examined the current...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40819167
DOI: 10.1038/s41523-025-00811-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bridging the gap: ctDNA, genomics, and equity in breast cancer carePMID 40819167Read ↗

Circulating Tumor DNA in Breast Cancer: Current and Future Applications.Semantic proximity Read ↗

Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applicationsSemantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.Semantic proximity Read ↗

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.Semantic proximity Read ↗

Bridging Discovery and Treatment: Cancer BiomarkerSemantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

Cell-free DNA comparative analysis of genomic landscape of first-line hormone-receptor positive metastatic breast cancer from US and ChinaSemantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Next-generation sequencing in breast cancer: current clinical applications and future directionsSemantic proximity Read ↗

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.